Evidence map›Paper›PMID 39099240›Full record

Observational studyAnnals of clinical and translational neurology2024

Application of the international criteria for optic neuritis in the Acute Optic Neuritis Network.

Philipp Klyscz, Susanna Asseyer, Ricardo Alonso, Charlotte Bereuter, Omer Bialer, Atira Bick, Sara Carta, John J Chen, Leila Cohen, Yamit Cohen-Tayar and 41 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Annals of clinical and translational neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

51 authors.

Philipp Klyscz *Experimental and Clinical Research Center, A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0003-0058-2365
Susanna Asseyer *Experimental and Clinical Research Center, A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0001-6289-1791
Ricardo AlonsoUniversity Center of MS and NMOSD, Neurology Department, Ramos Mejia Hospital, Buenos Aires, Argentina.
Charlotte BereuterExperimental and Clinical Research Center, A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.
Omer BialerDepartment of Neuro-Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
Atira BickDepartment of Neurology, Hadassah Medical Center, Hebrew University, Jerusalem, Israel.
Sara CartaNeurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy.
John J ChenDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Leila CohenUniversity Center of MS and NMOSD, Neurology Department, Ramos Mejia Hospital, Buenos Aires, Argentina.
Yamit Cohen-TayarDepartment of Neuro-Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
Edgar Carnero ContenttiNeuroimmunology Unit, Department of Neuroscience, Hospital Aleman, Buenos Aires, Argentina.
Russell C DaleTY Nelson Department of Paediatric Neurology, Children's Hospital at Westmead, Sydney, New South Wales, Australia.ORCID 0000-0002-2495-1826
Eoin P FlanaganDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Jonathan A GernertInstitute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany.
Julian HaasExperimental and Clinical Research Center, A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.
Joachim HavlaInstitute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany.
Christoph HeesenInstitute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg Eppendorf, Hamburg, Germany.
Mark HellmannDepartment of Neuro-Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
Netta LevinDepartment of Neurology, Hadassah Medical Center, Hebrew University, Jerusalem, Israel.ORCID 0000-0002-6111-6475
Pablo LopezNeuroimmunology Unit, Department of Neuroscience, Hospital Aleman, Buenos Aires, Argentina.
Itay LotanSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0002-4015-9783
Maria Belen LuisUniversity Center of MS and NMOSD, Neurology Department, Ramos Mejia Hospital, Buenos Aires, Argentina.
Sara MariottoNeurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy.ORCID 0000-0002-7806-3103
Christina MayerInstitute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg Eppendorf, Hamburg, Germany.
Alvaro Jose Mejia VergaraOphthalmology Department, University of Florida, Gainesville, Florida, USA.
Cassandra OcampoFaculty of Medicine, University of Botswana, Gaborone, Botswana.
Susana OchoaUniversity Center of MS and NMOSD, Neurology Department, Ramos Mejia Hospital, Buenos Aires, Argentina.
Frederike C OertelExperimental and Clinical Research Center, A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0003-4906-5983
Maja OlszewskaNeuroscience Clinical Research Center (NCRC), Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
José Luis Peralta UribePontificia Universidad Javeriana and Hospital Universitario San Ignacio, Bogotá, Colombia.
Jaume Sastre-GarrigaNeurology Department, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain.ORCID 0000-0002-1589-2254
Dario ScoccoUniversity Center of MS and NMOSD, Neurology Department, Ramos Mejia Hospital, Buenos Aires, Argentina.
Sudarshini RamanathanFaculty of Medicine and Health and Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-0294-9768
Natthapon RattanathamsakulFaculty of Medicine Siriraj Hospital, Mahidol University Bangkok, Bangkok, Thailand.ORCID 0000-0002-1698-0520
Fu-Dong ShiDepartment of Neurology, Tianjin Medical University General Hospital, Tianjin, China.ORCID 0000-0002-9675-4637
Jemal ShifaDepartment of Surgery, University of Botswana, Gaborone, Botswana.
Ilya SimantovDepartment of Neuro-Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
Sasitorn SirithoFaculty of Medicine Siriraj Hospital, Mahidol University Bangkok, Bangkok, Thailand.
Alon TiosanoDepartment of Neuro-Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
Nanthaya TisavipatDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-4021-6450
Isabel TorresPontificia Universidad Javeriana and Hospital Universitario San Ignacio, Bogotá, Colombia.
Adi Vaknin DembinskyDepartment of Neurology, Hadassah Medical Center, Hebrew University, Jerusalem, Israel.
Angela Vidal-JordanaNeurology Department, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain.
Adi Wilf-YarkoniNeuroimmunology Service, Department of Neurology, Rabin Medical Center, Petah Tikva, Israel.
Ti WuDepartment of Neurology, Tianjin Medical University General Hospital, Tianjin, China.
Sol ZamirDepartment of Neurology, Hadassah Medical Center, Hebrew University, Jerusalem, Israel.
Luis Alfonso ZarcoPontificia Universidad Javeriana and Hospital Universitario San Ignacio, Bogotá, Colombia.
Hanna G ZimmermannExperimental and Clinical Research Center, A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-0276-8051
Axel PetzoldThe National Hospital for Neurology and Neurosurgery, University College London, London, UK.
Friedemann PaulExperimental and Clinical Research Center, A Cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-6378-0070
Hadas Stiebel-KalishDepartment of Neuro-Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.

Funding

Deutsche Forschungsgemeinschaft (DFG) EXC-2049-390688087
6 · The paper itself

Abstract

objectiveThe first international consensus criteria for optic neuritis (ICON) were published in 2022. We applied these criteria to a prospective, global observational study of acute optic neuritis (ON).

methodsWe included 160 patients with a first-ever acute ON suggestive of a demyelinating CNS disease from the Acute Optic Neuritis Network (ACON). We applied the 2022 ICON to all participants and subsequently adjusted the ICON by replacing a missing relative afferent pupillary defect (RAPD) or dyschromatopsia if magnetic resonance imaging pathology of the optical nerve plus optical coherence tomography abnormalities or certain biomarkers are present.

resultsAccording to the 2022 ICON, 80 (50%) patients were classified as definite ON, 12 (7%) patients were classified as possible ON, and 68 (43%) as not ON (NON). The main reasons for classification as NON were absent RAPD (52 patients, 76%) or dyschromatopsia (49 patients, 72%). Distribution of underlying ON etiologies was as follows: 78 (49%) patients had a single isolated ON, 41 (26%) patients were diagnosed with multiple sclerosis, 25 (16%) patients with myelin oligodendrocyte glycoprotein antibody-associated disease, and 15 (9%) with neuromyelitis optica spectrum disorder. The application of the adjusted ON criteria yielded a higher proportion of patients classified as ON (126 patients, 79%).

interpretationAccording to the 2022 ICON, almost half of the included patients in ACON did not fulfill the requirements for classification of definite or possible ON, particularly due to missing RAPD and dyschromatopsia. Thorough RAPD examination and formal color vision testing are critical to the application of the 2022 ICON.

Indexed as

Optic NeuritisAcute DiseaseAdultFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedProspective StudiesTomography, Optical CoherenceYoung Adult

Identifiers

PMID39099240
PMCPMC11537134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.